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Abstract
Background: Low back disorders are a common and costly cause of pain and activity limitation in adults. Few
treatment options have demonstrated clinically meaningful benefits apart from advice which is recommended in
all international guidelines. Clinical heterogeneity of participants in clinical trials is hypothesised as reducing the
likelihood of demonstrating treatment effects, and sampling of more homogenous subgroups is recommended.
We propose five subgroups that allow the delivery of specific physiotherapy treatment targeting the
pathoanatomical, neurophysiological and psychosocial components of low back disorders. The aim of this article is
to describe the methodology of a randomised controlled trial comparing specific physiotherapy treatment to
advice for people classified into five subacute low back disorder subgroups.
Methods/Design: A multi-centre parallel group randomised controlled trial is proposed. A minimum of 250
participants with subacute (6 weeks to 6 months) low back pain and/or referred leg pain will be classified into one
of five subgroups and then randomly allocated to receive either physiotherapy advice (2 sessions over 10 weeks)
or specific physiotherapy treatment (10 sessions over 10 weeks) tailored according to the subgroup of the
participant. Outcomes will be assessed at 5 weeks, 10 weeks, 6 months and 12 months following randomisation.
Primary outcomes will be activity limitation measured with a modified Oswestry Disability Index as well as leg and
back pain intensity measured on separate 0-10 Numerical Rating Scales. Secondary outcomes will include a 7-point
global rating of change scale, satisfaction with physiotherapy treatment, satisfaction with treatment results, the
Sciatica Frequency and Bothersomeness Scale, quality of life (EuroQol-5D), interference with work, and psychosocial
risk factors (Orebro Musculoskeletal Pain Questionnaire). Adverse events and co-interventions will also be measured.
Data will be analysed according to intention to treat principles, using linear mixed models for continuous
outcomes, Mann Whitney U tests for ordinal outcomes, and Chi-square, risk ratios and risk differences for
dichotomous outcomes.
Discussion: This trial will determine the difference in outcomes between specific physiotherapy treatment tailored
to each of the five subgroups versus advice which is recommended in guidelines as a suitable treatment for most
people with a low back disorder.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000834257.
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Low back disorders (LBD) affect up to 84% of people at
some point in their lives [1], creating high rates of activ-
ity limitation, work absence, impaired quality of life and
the need for medical care [2]. The economic burden
resulting from LBD is high [3]. While it has often been
thought that the prognosis for most people with acute
LBD is favourable, ongoing or recurring pain and activ-
ity limitation are common [4-7].
A variety of treatments have been developed and evalu-
ated for people with LBD. While several have been
s h o w nt ob es u p e r i o rt op l a c e b oo rn ot r e a t m e n t ,c o m -
parisons between treatments rarely demonstrate clinically
meaningful differences [8-10]. One proposed explanation
for these results is clinical heterogeneity of participants
within randomised controlled trials [11,12]. Sample het-
erogeneity can diminish the chance of finding a signifi-
cant treatment effect due to the reduced proportion of
the sample for whom the treatment is appropriate [12].
In an attempt to overcome participant heterogeneity, a
number of classification systems have been proposed for
identifying subgroups of people with LBD who might
respond more predictably to specific treatment [12,13].
It has been recommended that future randomised con-
trolled trials should incorporate the use of subgroups in
the hope that larger effect sizes may result [12,14]. This
approach is consistent with clinical practice where most
clinicians aim to identify subgroups and provide a tai-
lored treatment program [11].
One approach to classification of LBD is to subgroup
people based on the known or hypothesised causal factors
[12,15]. This allows specifict r e a t m e n t st ob ed e v e l o p e d
targeting the causal mechanisms of the disorder [12,16].
The evolution of surgical discectomy to relieve radiculopa-
thy cased by a herniated intervertebral disc is an example
of this method targeting a pathoanatomical causal
mechanism [17,18]. In that case, validation of the classifi-
cation approach is evident from studies showing that dis-
cectomy surgery performed on participants with
radiculopathy from a herniated disc results in superior
short and intermediate term pain and activity outcomes
compared to other treatments [19,20].
Given the multifactorial nature of LBD, factors other
than the pathoanatomical source of pain also need to be
considered in a robust classification approach [12],
including neurophysiological [21,22] and psychosocial
components of LBD [23,24]. The duration of injury is
also considered an important factor in the presentation
and prognosis of people with LBD [24-26]. We are inter-
ested in investigating specific physiotherapy treatment
strategies in the subacute population of LBD, where
spontaneous recovery is less rapid and the complex issues
associated with chronic pain are less likely to be fully
entrenched [4,6,27]. In the context of such a population,
we have developed specific treatment protocols for five
LBD subgroups that consider pathoanatomical, neuro-
physiological and psychosocial mechanisms. The five
subgroups are i) lumbar disc herniation with associated
radiculopathy (Ford JJ, Hahne AJ, Chan AYP: A classifi-
cation and treatment protocol for low back disorders:
Part 3- Functional restoration for intervertebral disc
related problems, submitted); ii) reducible discogenic
pain (Ford JJ, Surkitt LD, Hahne AJ: A classification and
treatment protocol for low back disorders: Part 2- Direc-
tional preference management for reducible discogenic
pain, submitted); iii) non-reducible discogenic pain (Ford
JJ, Hahne AJ, Chan AYP: A classification and treatment
protocol for low back disorders: Part 3- Functional
restoration for intervertebral disc related problems, sub-
mitted); iv) zygapophyseal joint dysfunction [28] and; v)
multi-factorial persistent pain (Ford JJ, Richards MC,
Hahne AJ: A classification and treatment protocol for
low back disorders: Part 4- Functional restoration for
multi-factorial persistent pain, submitted). These five
subgroups have been chosen based on i) their common
recognition by clinicians [29-31]; ii) their description in
another pathoanatomical classification system [15,32]
and; iii) significant evidence of subgroup reliability and
validity [15,32,33].
A randomised controlled trial is planned to evaluate
the effectiveness of the subgroup-specific treatment.
Advice will be the comparison intervention as it is
recommended in all international guidelines for the
management of LBD [34] and has demonstrated efficacy
in randomised controlled trials [35-37].
The aim of this paper is to describe the design of a
randomised controlled trial comparing specific phy-
siotherapy treatment to physiotherapy advice for people
classified into five subacute LBD subgroups.
Methods/Design
Study design
This will be a multi-centre parallel group randomised
controlled trial. An overview of the process of the trial
is presented in Figure 1.
Ethics and registration
The trial has received ethical approval from the La
Trobe University Human Ethics Committee, and has
been registered with the Australian New Zealand Clini-
cal Trials Registry (#12609000834257).
Setting
The treatments will be conducted at private physiother-
apy practices that are part of the Spinal Management
Clinics of Victoria network throughout metropolitan
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network as a source of treatment centres and practi-
tioners due to existing quality assurance procedures as
well as training and mentoring programs that are acces-
sible for the purposes of the trial.
Eligibility and screening
Participants will be sought via newspaper advertising,
public notices, and via referral from medical practi-
tioners and physiotherapists. Potential participants will
initially undergo a preliminary screening for eligibility
Enquiry regarding trial received via phone, 
facsimile or email
Telephone screening conducted
Physical assessment conducted (including 
completion of baseline questionnaires)
Consent form signed
Consenting participants assigned to one of 
five subgroups based on their classification
Exclude ineligible 
volunteers
Exclude non-consenting 
volunteers
Advice group Specific physiotherapy group
5 week follow-up 5 week follow-up
10 week follow-up 10 week follow-up
26 week follow-up 26 week follow-up
52 week follow-up
Randomisation (stratified for subgroup and 
treatment centre)
52 week follow-up
Exclude ineligible 
volunteers
Figure 1 Overview of participant flow through the trial.
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mon to all subgroups and are outlined in Table 1.
Those found to be potentially eligible will be invited to
attend a physical examination with one of the treating
physiotherapists. The physical examination will i) con-
firm eligibility; ii) determine which subgroup (if any) the
participant fits and; iii) provide descriptive information
on the baseline characteristics of participants. The phy-
sical examination will involve:
￿ Observation of the spine for evidence of postural
deformity such as a lateral shift or an increased or
decreased lumbar lordosis [38], using protocols with
acceptable reliability [39,40].
￿ Measurement of lumbar spine active movements
into flexion, extension and lateral-flexion using fin-
ger-to-floor measurement methods that have been
shown to be reliable [41].
￿ Lower limb neurological examination in a seated
position, which will involve testing of knee jerk and
ankle jerk reflexes, myotomal strength testing and
dermatomal sensation in response to light touch
with a tissue [42]. Acceptable reliability for these
tests has been demonstrated in people with sus-
pected lower limb nerve root compression [42].
￿ Straight leg raise and crossed straight leg raise,
which will be considered positive if the participant’s
usual lower limb symptoms are reproduced at any
angle during passive raising of either leg by the
examiner [42]. The reliability of this test is consid-
ered good when performed on people with suspected
nerve root compression [42].
￿ Prone knee flexion test, which will be considered
positive if the participant’s usual anterior thigh
symptoms are reproduced at any angle [43,44].
The reliability of this test has been shown to be
good in people with suspected nerve root compres-
sion [42].
￿ Lumbar spine palpation performed with the partici-
pant prone, with the examiner applying pressure cen-
trally over the lumbar spinous processes and
unilaterally over the lumbar zygapophyseal joints and/
or transverse processes [45]. Where a localised painful
or stiff segment is identified, a “mini-treatment” will be
undertaken consisting of a 30-second low grade mobili-
sation of the joint, and the participant’sr e s p o n s ew i l lb e
recorded in terms of any changes in pain or range of
motion upon repeat testing [28,45]. Studies have
demonstrated good reliability for lumbar spine palpa-
tion [46,47].
Table 1 Eligibility criteria common to all subgroups
Inclusion criteria
1. A primary complaint of either:
a. low back pain, defined as pain between the inferior costal margin and the inferior gluteal fold with or without referral into the leg(s) [138,139],
or
b. referred leg pain, defined as predominately unilateral posterior leg pain extending below the knee, or anterior thigh pain, with or without back
pain (disc herniation with associated radiculopathy subgroup only) [56]
2. Duration of current episode of primary complaint lasting between 6 weeks and 6 months (subacute stage of injury [27,140]), with at least a 4
week pain-free period separating the current episode from any previous episodes [141,142]
3. Aged between 18 and 65 (inclusive)
4. Fluency in English sufficient to complete questionnaires and to enable understanding of the intervention
5. Classified into one of the five subgroups of low back disorders being targeted in the trial
6. Agreeing to refrain from other interventions wherever possible for the 10-week treatment period of the trial, aside from consultations with
medical practitioners, medication, and any exercises already being undertaken
Exclusion criteria
1. An active compensation claim for their back injury, due to the negative influence that this can have on prognosis [125]
2. Active cancer under current treatment, as the treatment of the cancer may interfere with their ability to participate in the trial
3. Signs of cauda equina syndrome based on bladder or bowel disturbance and/or imaging [143]
4. Current pregnancy, or childbirth within the last 6 months, as this could impair ability to undertake exercises, and could also cause back and leg
symptoms that are not related to the subgroups under investigation
5. Spinal injections within the last 6 weeks, as we wish to study treatment effects independent to the effects of injections [144]
5. Any history of lumbar spine surgery, as there is already considerable research evaluating the efficacy of post-surgical rehabilitation programs [145]
6. A pain intensity score of less than 2/10 on a 0-10 numerical rating scale due to low severity
7. Minimal activity limitation, evidenced by a baseline ability to walk, sit and stand for one hour or more and no sleep disturbance at night, as we
wish to exclude people with low severity
8. Already received more than 5 sessions of physiotherapy with any of the treating physiotherapists prior to enrolment, as these therapists are likely
to use many components of the trial treatment protocol on their usual client caseload
9. Inability to walk safely, such as severe foot drop causing regular tripping, as the interventions in the trial include walking for most participants
10. Planned absence of more than one week during the treatment period (such as overseas holidays)
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prone positioning and repeated extension move-
ments in a prone position (with or without lateral
shift of the pelvis), which will be assessed to deter-
mine whether a directional preference is present.
Directional preference will be defined as the direc-
tion of movements or postures that result in either
centralisation of symptoms, sustained decrease in
symptoms (by at least 1 point on a 0-10 numerical
rating scale) or improvement in range-of-motion fol-
lowing the assessment of mechanical loading strate-
gies [48-50]. Assessing for a directional preference
has been shown to be reliable [50,51].
￿ Determination of the participant’s ability to acti-
vate the transversus abdominis via a localised inward
movement of the lower abdominal wall in a standing
position which will be visualised and palpated using
a reliable method [52,53]. Each participant’s ability
to activate the lumbar multifidus via localised gen-
eration of tension will also be assessed via palpation
of the participant in prone. Although therapist pal-
pation is one recommended method of assessing the
activation of multifidus [53], studies evaluating the
reliability of this method could not be located.
Participants will also complete the Subjective Com-
plaints Questionnaire, which is a valid and reliable self-
administered tool for gaining subjective information
relating to the history of back and leg symptoms, the
mechanism of onset, and the nature and behaviour of
symptoms [54].
Classification
Data from the Subjective Complaints Questionnaire and
the physical examination will be used to classify partici-
pants into one of the five pre-defined subgroups, i) disc
herniation with associated radiculopathy; ii) reducible
discogenic pain; iii) non-reducible discogenic pain; iv)
zygapophyseal joint dysfunction and; v) multi-factorial
persistent pain. A Microsoft Excel
a spreadsheet contain-
ing a decision rule algorithm will be used to reliably
identify subgroup membership after examination and
questionnaire data have been entered.
The five subgroups targeted in this trial do not repre-
sent an exhaustive classification system for LBD. People
w h od on o tf i ti n t oo n eo ft h es u b g r o u p sw i l lb e
excluded from the trial. Detailed justification for each of
the subgroups is reported elsewhere (Ford JJ, Surkitt
LD, Hahne AJ: A classification and treatment protocol
for low back disorders: Part 2- Directional preference
management for reducible discogenic pain, submitted;
Ford JJ, Hahne AJ, Chan AYP: A classification and treat-
ment protocol for low back disorders: Part 3- Functional
restoration for intervertebral disc related problems,
submitted; Ford JJ, Richards MC, Hahne AJ: A classifica-
tion and treatment protocol for low back disorders: Part
4- Functional restoration for multi-factorial persistent
pain, submitted; [15,28,32]). An overview of the decision
rule algorithm for classifying participants into subgroups
is presented in Figure 2. A description of the five sub-
groups to be included in the trial is presented below.
Disc herniation with associated radiculopathy
To be classified in this subgroup, participants will have
i) referred leg symptoms (below the knee for L3/4, L4/5
or L5/S1 herniations, or into the anterior thigh for L1/2,
L2/3 or L3/4 herniations); ii) at least one clinical exami-
nation sign suggestive of radiculopathy (reduced reflex,
reduced dermatomal sensation, reduced myotomal
strength, reproduction of usual leg symptoms on
straight leg raise or reproduction of usual anterior thigh
symptoms on prone-knee-flexion testing) and; iii) a
Computerised Tomography (CT) or Magnetic Reso-
nance Imaging (MRI) scan demonstrating a lumbar disc
herniation consistent with the examination findings
[55,56].
Reducible discogenic pain
To be classified in this subgroup, participants will pre-
sent with at least four out of nine features indicative of
discogenic low back pain. The features have been identi-
fied through literature searching, consideration of causal
mechanisms and the results of a Delphi study of experts
in the field (Chan AYP, Ford JJ, McMeeken JM, Wilde
VE: Features of non-reducible discogenic low back pain:
survey of an international expert panel with the Delphi
technique, submitted). The features are:
1) Presence of low back pain with or without leg
pain
2) Sitting limited to less than 60 minutes
3) Symptoms worse the next morning or next day
following the initial injury
4) History of working in a job involving manual
handling
5) A mechanism of injury associated with flexion/
rotation and/or compression loading
6) At least some difficulty with forward bending
7) At least some difficulty with lifting
8) At least some difficulty with sit-to-stand
9) At least some difficulty with coughing/sneezing.
Participants will also demonstrate a directional pre-
ference in response to mechanical loading strategies on
physical examination. The presence of a directional
preference has been proposed as identifying people
likely to have discogenic pain where a posterior or
posterolaterally migrated nucleus pulposus can be
“reduced” into a more central and non pain provoking
position [15,50].
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To be classified in this subgroup, participants will have
at least four out of nine signs of discogenic pain as out-
lined above for the reducible discogenic pain subgroup.
However, participants who do not demonstrate a direc-
tional preference in response to mechanical loading stra-
tegies will be classified in the non-reducible (rather than
reducible) discogenic pain subgroup provided they do
not satisfy the selection criteria for the zygapophyseal
joint dysfunction group.
Zygapophyseal joint dysfunction
This group will comprise participants believed to have
zygapophyseal joint dysfunction as the primary source
of their back symptoms. To be classified in this sub-
group, participants will have at least three of the follow-
ing four features of zygapophyseal dysfunction, i)
presence of unilateral low back pain; ii) a regular com-
pression pattern (pain reproduced with lumbar exten-
sion and ipsilateral lateral-flexion movements); iii)
localised pain on ipsilateral passive postero-anterior
accessory movement applied through the transverse pro-
cess or the zygapophyseal joint at one or two segments
and; iv) improvement in pain or range-of-movement
following a “mini-treatment” of manual therapy directed
at the zygapophyseal joint [28].
Multi-factorial persistent pain
Participants without a clear pathoanatomical classification
(ie. they do not fit one of the other four pathoanatomical
subgroups), who also have an Orebro Musculoskeletal
Pain Questionnaire score greater than 105, will be classi-
fied as belonging to this subgroup. In these participants it
is hypothesised that psychosocial and/or neurophysiologi-
cal factors may be negatively impacting their recovery.
Randomisation and allocation
Eligible participants who provide written consent to par-
ticipate will be randomised into one of two treatment
groups; advice or specific physiotherapy treatment. A
randomisation schedule will be prepared in advance by a
researcher (NT) who will have no contact with any parti-
cipants throughout the trial and will not be involved in
the recruitment, screening, assessment, enrolment or
treatment process. The randomisation sequence will be
generated using a web-based randomisation program
(http://www.randomization.com) with the sequence
transferred into a computer spreadsheet. Permuted block
Data obtained from baseline 
physical assessment and 
questionnaires
Is radiculopathy 
present?
NO
Are at least 4 discogenic 
features present?
YES
NO
Does assessment of 
mechanical loading strategies 
indicate the disc is reducible?
Are at least 3 zygapophyseal 
joint features present?
NO
Does a CT / MRI scan show a 
lumbar disc herniation 
consistent with the clinical 
signs of radiculopathy?
Are at least 3 zygapophyseal 
joint features present?
YES
YES
Disc herniation with 
radiculopathy (DHR)
NO
Does the CT / MRI scan show 
another cause of 
radiculopathy (eg. spinal 
stenosis, spondylolisthesis)?
YES
Exclude. Potential 
alternative cause of 
radiculopathy
NO
YES Reducible discogenic pain 
(RDP)
NO
Non-reducible discogenic 
pain (NRDP)
YES
Zygapophyseal joint 
dysfunction (ZJD)
NO
Is the Örebro score > 
105?
YES
Multi-factorial persistent 
pain (MFP)
NO
Exclude. Does not 
ﬁt any subgroup
YES
Figure 2 Decision rule algorithm for classifying participants into subgroups.
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avoid unequal group sizes [57]. Randomisation will be
stratified for subgroup and treatment centre by generat-
ing a separate schedule for each combination of subgroup
and centre.
Allocation of participants in accordance with the ran-
domisation schedule will be undertaken by an adminis-
trative assistant who will be the only person with access
to the allocation spreadsheet during the trial. The admin-
istrative assistant will not be involved in the recruitment,
screening, assessment, enrolment, or treatment of partici-
pants, and will be located at a separate site to all treat-
ment centres [58]. To enrol a participant, the treating
physiotherapist will email the consenting participant’s
name and date of birth to the administrative assistant
along with their subgroup classification and treatment
centre. These details will be entered into the allocation
spreadsheet and the next treatment allocation and parti-
cipant identification number will be emailed back to the
treating physiotherapist.
Treatment protocols
Two different 10-week physiotherapy programs will be
compared. The protocols for each intervention will be
outlined in a detailed treatment manual, supplemented
by electronic “clinical notes” which will contain an out-
line of the treatment protocol on a session-by-session
basis. The clinical notes will prompt treating physiothera-
pists regarding the mandatory and optional treatment
components for each session. The clinical notes will
require the treating physiotherapists to document assess-
ment/reassessment findings, clinical reasoning/decision
making rationale, treatment provided and response to
treatment during each session.
Comparison intervention: physiotherapy advice
Participants allocated to the physiotherapy advice inter-
vention will attend two 30-minute physiotherapy sessions
with one of the treating physiotherapists during a
10-week period. The intervention will follow the
approach described by Indahl et al. [35], which consists
of providing a pathological explanation of the partici-
pant’s pain, reassurance regarding the generally favour-
able prognosis of their condition, advice to remain active
and instruction regarding correct lifting technique.
Advice is recommended in all international low back
pain guidelines [34] and has demonstrated efficacy in
randomised controlled trials [35-37].
Primary intervention: specific physiotherapy treatment
Participants allocated to the specific physiotherapy inter-
vention will attend ten 30-minute physiotherapy sessions
over a 10-week period. The content of the sessions will
relate to known or hypothesised mechanisms underpinning
each of the five subgroups. Within each subgroup, treat-
ment methods will be clearly defined and standardised via
detailed session-by-session clinical notes that contain a
series of decision making algorithms. The algorithms and
clinical notes will ensure that essential elements of the
treatment program are consistently applied by all phy-
siotherapists across all participants, while still allowing
some opportunity for the treatment to be tailored to indivi-
dual participants. Information provided to participants will
be standardised via a series of pre-prepared participant
information sheets specific for each subgroup. The treat-
ment components, participant handouts and decision mak-
ing algorithms are based on existing protocols developed
by a senior musculoskeletal physiotherapist (JF). These
have been refined via systematic reviews of the effective-
ness of interventions for each subgroup that were underta-
ken by members of the research team, one of which has
been published to date [20]. A full day meeting was also
attended by five members of the research team and eight
physiotherapists who planned to treat participants in the
trial, with the aim of evaluating the suitability and clinical
utility of the selected treatment components for each sub-
group. Separate articles fully describe the rationale and
detailed application of the specific physiotherapy treatment
protocols for each subgroup (Ford JJ, Surkitt LD, Hahne
AJ: A classification and treatment protocol for low back
disorders: Part 2- Directional preference management for
reducible discogenic pain, submitted; Ford JJ, Hahne AJ,
Chan AYP: A classification and treatment protocol for low
back disorders: Part 3- Functional restoration for interver-
tebral disc related problems, submitted; Ford JJ, Richards
MC, Hahne AJ: A classification and treatment protocol for
low back disorders: Part 4- Functional restoration for
multi-factorial persistent pain, submitted; [28]). In the cur-
rent paper, a summary of the mandatory and optional
treatment components for the specific physiotherapy treat-
ment arm is presented below for each subgroup and a list
of all components is contained in Table 2.
The main component of treatment in the disc hernia-
tion with associated radiculopathy subgroup and the
non-reducible discogenic pain subgroup will be a func-
tional restoration program modified for the presence of
discogenic pathology. The content of the program will
be similar for both subgroups but the nature of the
pathoanatomical information will be specific to each
subgroup. Specific motor control training targeting the
core stabilising muscles (transversus abdominis, lumbar
multifidus and pelvic floor muscles) will initially be
taught in non-weight bearing positions [53]. This will
then be progressed into functional exercises relevant to
each participant’s work and daily activities with the aim
of restoring function and normal motor control during
these tasks. A detailed case study of a person with disc
herniation with associated radiculopathy who was trea-
ted using this approach has been published previously
[59].
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treatment for the reducible discogenic pain subgroup
will involve directional preference management based
on the McKenzie method [38]. Initial and subsequent
assessments will identify the direction of repeated move-
ments or sustained positions that lead to improvement
or centralisation of the participant’sp a i n .A d v i c e ,p o s -
tural strategies and exercises will then be implemented
in order to promote movements and positions corre-
sponding with this directional preference. Once the
directional preference management has been established,
all participants in this subgroup will commence specific
motor control training in non-weight bearing positions
which will then be progressed into functional exercises
to be completed at home.
For participants in the zygapophyseal joint dysfunction
subgroup, the focus of the specific physiotherapy
treatment will be manual therapy [45]. Available techni-
ques will include passive accessory movements, passive
physiological rotation mobilisation, and high velocity
thrust rotary manipulation [45]. Detailed clinical reason-
ing processes will be facilitated via the clinical notes to
assist physiotherapists to select the most appropriate
manual therapy techniques, and then to progress them
appropriately based on the participant’s clinical response
[45]. Physiotherapists will have flexibility to explore other
manual treatment techniques based on the results of a
“mini-treatment”, however the utilisation of key clinical
reasoning principles will be mandatory. As per the redu-
cible discogenic pain subgroup, specific motor control
training will be integrated into a home based functional
exercise program later in the treatment protocol.
The multi-factorial persistent pain subgroup will
receive specific physiotherapy treatment based on an
Table 2 Components of each treatment protocol used in the trial
Treatment component DHR NRDP RDP ZJD MFP Advice
Patho-anatomical/physiological explanation including generally favourable prognosis ✔✔ ✔✔ X ✔
Advice in accordance with Indahl et al. [35] X X X X X ✔
Explanation of pain physiology and central sensitisation for ongoing pain with multiple biopsychosocial
contributing factors
OO OO ✔ X
Discussion of treatment options available ✔✔ ✔✔ ✔X
Discussion of timeframes and expectations ✔✔ ✔✔ ✔X
Posture education including lifting technique ✔✔ ✔OX X
Teaching pacing and graded exposure strategies ✔✔ ✔O ✔ X
Goal setting (establishment and regular reviews) ✔✔ ✔✔ ✔X
Specific motor control training (transversus abdominis, lumbar multifidus and pelvic floor) ✔✔ ✔✔ OX
Teaching and supervision of functional restoration exercises in the clinic with additional sessions at home ✔✔ XX✔ X
Demonstration of functional restoration exercises for implementation at home X X ✔✔XX
Education regarding pain management strategies (pharmacological) O O O O O X
Education regarding pain management strategies (non-pharmacological) O O O O O X
Strategies to control inflammation O O O O O X
Application of strapping tape to lumbar spine ✔✔ ✔OX X
Discussion of strategies to manage work issues O O O O O X
Directional preference management (McKenzie program)...includes mechanical loading strategies, repeated
movements, walking program, taping, and postural advice
OO ✔ XX X
Manual therapy XX X✔ XX
Relaxation strategies OO OO OX
Sleep strategies OO OO OX
Management of increases in pain O O O O X X
Explanation of improvement in function V’s improvement in pain O O O O X X
Cognitive restructuring of counterproductive beliefs (via use of information sheets relating to the above
treatment components)
✔✔ ✔✔ ✔X
Behavioural strategies to support and reinforce the education and information provided and to modify
unproductive behaviours
✔✔ ✔✔ ✔X
Transfer to MFP protocol if inadequate progress with pathoanatomical approach after five sessions O O O O X X
Targeted cognitive restructuring and behavioural modification based on review of the Orebro
Musculoskeletal Pain Questionnaire subscales
XX XX ✔ X
Specific discussion of psychosocial barriers as an explanation for failure to recover O O O O ✔ X
Discharge planning for long-term management ✔✔ ✔✔ ✔X
✔ = component mandatory, O = component optional/if required, X = component not allowed, DHR = disc herniation with associated radiculopathy, NRDP =
non-reducible discogenic pain, RDP = reducible discogenic pain, ZJD = zygapophyseal joint dysfunction, MFP = multi-factorial persistent pain.
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mical subgroups. Unlike the other subgroups, there will
be minimal use of treatment strategies relating to
pathoanatomical mechanisms. The focus of treatment
for this subgroup will be i) detailed education in relation
to the neurophysiology of pain and maladaptive central
processing [60,61]; and b) a functional restoration pro-
gram to promote graded exercise and increased function
[62,63]. In addition, there will be an emphasis on the
use of cognitive restructuring and behavioural strategies
targeting key barriers identified via the Orebro Muscu-
loskeletal Pain Questionnaire.
While the main focus of the specific physiotherapy
treatment protocol will differ for each subgroup in the
trial, several mandatory and optional treatment compo-
nents will be common across subgroups. These include
education regarding treatment options and expected
recovery timeframes, goal setting, pacing, graded activ-
ity, cognitive restructuring and behavioural modification
strategies, pain management strategies, sleep manage-
ment, relaxation strategies, and management of inflam-
mation (see Table 2).
Participating physiotherapists
Physiotherapists from within a network of private prac-
tices (Spinal Management Clinics of Victoria) will pro-
vide the treatment for both groups. To be eligible,
physiotherapists will need to have worked within the
network for at least six months, have completed an
initial two-day training program and be engaged with an
ongoing clinical mentoring program.
All physiotherapists will undergo an additional one-day
training program led by one of the researchers (JF) where
the assessment and treatment protocols will be taught.
This will be supplemented by an extensive manual out-
lining all assessment, treatment and trial protocols. For
the duration of the trial a monthly teleconference will be
undertaken for 60 minutes involving all treating phy-
siotherapists to review specific cases in the context of the
treatment protocols. Evaluation of treatment integrity
a n dc o m p l i a n c eb yt h ep h y s iotherapists for both the
advice and the specific physiotherapy interventions will
be achieved by checking the physiotherapist’s clinical
notes for each participant at week four, week seven and
week ten of their program.
Outcome assessment
Outcomes will all be assessed via a booklet of self-admi-
nistered questionnaires that will be mailed to partici-
pants prior to the initial physical examination and at
each of the follow-up points (5 weeks, 10 weeks, 26
weeks and 52 weeks post randomisation). Participants
will return completed follow-up questionnaires to the
researchers via mail marked only with their participant
identification number. The outcomes to be measured in
the trial are summarised in Table 3.
Primary outcome measures
Activity limitation will be evaluated using nine questions
from the Oswestry Disability Index version 2.1 [64], with
the tenth question relating to “sex life” being replaced
by a question relating to “work/housework” [65,66].
Rasch analysis has shown that this modified version per-
forms as well as the original Oswestry [65], but it is
aimed at preventing missing responses to the “sex life”
question. The Oswestry has been shown to be a reliable,
valid and responsive instrument for measuring activity
limitation in people with low back pain and referred leg
pain [67-69].
Separate 0-10 numerical rating scales (NRS) will be
used to measure the average intensity of back pain and
leg pain over the past week, with end-point descriptors
of “no pain” and “worst pain possible” [70,71]. The NRS
has good reliability [72,73], responsiveness [74,75] and
validity [76,77].
Secondary outcome measures
Global rating of change will be measured using a 7-point
Likert scale, with participants rating their overall change
since the baseline assessment as “completely recovered”,
“much improved”, “slightly improved”, “no change”,
“slightly worsened”, “much worsened”,o r“vastly wor-
sened” [78,79]. Various versions of this scale are consid-
ered to be reliable, responsive and valid [79,80].
In addition to global rating of change, participants will
rate their satisfaction with physiotherapy treatment and
their satisfaction with the results of physiotherapy treat-
ment on separate 5-point Likert scales, with ratings
from “very satisfied” to “very dissatisfied” [81-83]. These
scales have good reliability, validity and responsiveness
[84,85].
The Sciatica Frequency and Bothersomeness Scale will
be used to assess the frequency and “bothersomeness” of
a range of leg symptoms including leg pain, numbness or
tingling, and weakness in the leg or foot [86]. This scale
has been used in a number of trials, particularly those
focussing on sciatica or disc herniation [56,87-89]. The
scale is considered to be a specific quality of life measure
and has compared favourably to the generic SF-36 in
people with LBD [86]. It has been shown to be reliable
[86,90], responsive, and valid [90,91].
Interference with work due to the LBD will be
assessed in two ways. Firstly, at each assessment point
participants will record the number of work days missed
due to their back/leg condition over the previous 30
days [81,82]. Secondly, participants will rate the degree
of interference with work (employment or housework)
caused by their back/leg condition over the previous
w e e ko naf i v ep o i n ts c a l er a n g i n gf r o m“not at all” to
“extremely” [81,82]. These measurement methods have
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ness [84,85].
The Orebro Musculoskeletal Pain Questionnaire will
be used as a measure of psychosocial risk factors
[92,93]. Although it is more commonly used as a prog-
nostic screening tool at one point in time [94], in our
trial the Orebro will also be administered at each fol-
low-up point to detect changes in psychosocial risk fac-
tors over time. This appears justified given that the
Orebro has good test-retest reliability and internal con-
sistency [92,95], although its responsiveness as an out-
come measure is unclear.
Health-related quality of life will be measured with the
EuoQol-5D [96]. Utilities will be calculated according to
the validated algorithms of Dolan [97]. The EuroQol-5D
has good reliability, validity and responsiveness [98-100],
i sar e c o m m e n d e do u t c o m em e a s u r ef o rl o wb a c kp a i n
research [82] and has been used in several other low
back pain trials [101-103].
Adverse events
Adverse events will be measured in both groups using
t w om e t h o d s .F i r s t l y ,p h y s i o t h e r a p i s t sw i l lr e c o r da n y
adverse events that occur during the treatment period
on their standardised clinical notes for each participant,
and these will be submitted to the researchers after four
weeks, seven weeks and at the conclusion of the inter-
vention period (ten weeks). In addition, an open ques-
tion on all follow-up questionnaires will ask participants
to describe any adverse, harmful or unpleasant effects
that they attribute to the intervention.
Participant compliance and co-interventions
The number of physiotherapy treatment sessions
attended by each participant, and the number of missed
or cancelled appointments, will be recorded by the
treating physiotherapists. Participant compliance with
their physiotherapist’s advice and prescribed exercises
will also be reviewed by physiotherapists at each visit via
direct questioning and reviewing participants’ exercise
charts. Information regarding the nature and degree of
co-interventions as well as medication usage will be
obtained from participants on each follow-up outcome
questionnaire.
Data integrity
All questionnaire data will be scored and entered into a
computer spreadsheet by a researcher blinded to the
group allocation of the participant. Data will be checked
for omissions and outliers to identify potential data
entry errors and these will be clarified with the data
enterer.
Blinding
Given the nature of the interventions it will not be pos-
sible to blind participants or physiotherapists. However,
all physiotherapists and participants will be informed
that both treatment approaches are valid interventions
that have a realistic chance of being beneficial and that
neither approach is known to be more effective than the
other. Physiotherapists will also be instructed to treat
participants in both groups with the same degree of
rigor, enthusiasm and optimism.
Data analysis
Data analysis will focus on detecting the between-group
treatment effect (with 95% confidence intervals) at each
of the follow-up points (5 weeks, 10 weeks, 26 weeks
and 52 weeks following randomisation). Analyses will be
conducted using PASW Version 18
b, with alpha set at
0.05 using a two-tailed hypothesis. Continuous data will
be analysed using linear mixed models (with the group
Table 3 Outcome measures
Outcome measure Measurement point (weeks)
Primary outcome measures
1. Oswestry Disability Index V2.1 with “sex life” question replaced by a “work/housework” question 0, 5, 10, 26, 52
2. Numerical rating scale for back pain (0-10) 0, 5, 10, 26, 52
3. Numerical rating scale for leg pain (0-10) 0, 5, 10, 26, 52
Secondary outcome measures
1. Global rating of change scale (7-point Likert scale) 5, 10, 26, 52
2. Satisfaction with physiotherapy treatment (5-point Likert scale) 5, 10, 26, 52
3. Satisfaction with results of physiotherapy treatment (5-point Likert scale) 5, 10, 26, 52
4. Number of work days missed in the last 30 days 0, 5, 10, 26, 52
5. Interference with work or housework in the past week (5-point Likert scale) 0, 5, 10, 26, 52
6. Quality of life (EuroQol-5D) 0, 5, 10, 26, 52
7. Orebro musculoskeletal pain questionnaire 0, 5, 10, 26, 52
8. Sciatica frequency scale 0, 5, 10, 26, 52
9. Sciatica bothersomeness scale 0, 5, 10, 26, 52
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These were chosen for their strength in analysing longi-
tudinal biological data and accounting for correlations
associated with repeated measurements [104-106]. The
mixed models will adjust for the baseline score of the
outcome of interest, along with the stratification vari-
ables (treatment centre and subgroup) as recommended
by the revised CONSORT statement [107]. The inclu-
sion of treatment centre as a random effect will account
for the potential clusteringo fo u t c o m e sw i t h i nt r e a t -
ment centres [108,109]. In addition, the mixed models
will adjust for gender and Orebro Musculoskeletal Pain
Questionnaire score, as gender and psychosocial factors
are considered to be important prognostic factors [107].
Ordinal data will be analysed using the Mann Whitney
U test.
At each follow-up point, participants in each group
will be dichotomised according to whether they achieved
the minimum clinically important difference of the out-
come or not, and then the risk ratio, risk difference and
number needed to treat will be calculated along with
95% confidence intervals [107,110]. Statistical signifi-
cance will be evaluated using Chi square analysis. For
these purposes, the minimum clinically important differ-
ence will be defined as 10/100 for the Oswestry [111],
2/10 for the NRS pain scales [111], at least “much
improved” o nt h eg l o b a lr a t i n go fc h a n g es c a l e[ 7 1 , 1 1 2 ]
and “very satisfied” on the treatment satisfaction scales
[71]. It has been argued that these values for minimum
clinically important difference may be too low in some
contexts [113], hence we will repeat this analysis using a
threshold of 50% reduction in Oswestry scores and NRS
pain scores based on empirical validation studies sug-
g e s t i n gt h a tt h i sm a yb eam o r es u i t a b l et h r e s h o l df o r
important differences [67,114].
All data will be analysed on an intention to treat basis,
in that all participants will be analysed in the treatment
group to which they are initially allocated regardless of
their compliance with that treatment [107,115]. All par-
ticipants who withdraw from treatment for any reason
will continue to be contacted for follow-up assessments
and informed that their data are still required. Our pri-
mary method of analysis will not impute missing data
[116]. This is justified as all methods of data imputation
have limitations [107], and the linear mixed model ana-
lysis that we planned for analysing continuous data is
thought to inherently account for missing data in a
more effective and less biased manner than data imputa-
tion methods [105,106,117,118]. However, given the
popularity of simple data imputation methods [105,107]
we will undertake a secondary sensitivity analysis to
determine whether the results would differ if missing
data were replaced using the last observation carried
forward method.
In addition to the analyses described above, subgroup
analyses will be undertaken to estimate the effects of
specific treatment on each of the five subgroups within
the trial. This will be possible due to the stratification of
the randomisation for subgroup which will ensure that
each subgroup has a balanced allocation of participants
between the specific treatment and advice groups. Preli-
minary analysis will need to be undertaken on two of
the subgroups prior to the completion of the trial in
order for PhD thesis submission deadlines to be met. It
is often recommended that an alpha adjustment be
made when interim analyses are to be performed
[107,119]. However, in our trial the overall data from all
trial participants will not be analysed prior to the com-
pletion of recruitment, so no adjustment in alpha will
be made in the final analysis involving all participants.
Sample size
We will recruit a total sample size of at least 250 parti-
cipants. We would require 128 participants (64 in each
group) to detect the minimum clinically important dif-
ference between groups of 10% on the Oswestry assum-
ing a standard deviation of 20 (two tailed hypothesis,
alpha = 0.05, power = 80%) [120]. However, we wish to
recruit more than this to improve power in our planned
subgroup analyses. We acknowledge that the subgroup
analyses are likely to remain underpowered [121], but
they may provide some guidance for future research tar-
geting the subgroups with greatest feasibility and
effectiveness.
Discussion
In this randomised controlled trial we aim to compare
specific physiotherapy treatment to advice in people
with LBD classified into five subgroups. We hypothesise
that participants who receive specific physiotherapy
treatment according to their subgroup will achieve
superior clinical outcomes to those who receive phy-
siotherapy advice. We will be testing this hypothesis in
participants with subacute, non-compensable LBD. This
decision has been made to avoid inclusion of partici-
pants with negative prognostic indicators including
chronic symptoms [6,122,123] and compensable injuries
[124,125], as these participants may require more exten-
sive intervention than either of the treatment arms offer
in our trial. We will avoid including participants with
acute symptoms as this may lead to difficulty in demon-
strating treatment effects above the higher rate of initial
spontaneous recovery that might be expected in these
participants [4,6,7,27]. Importantly, there has been lim-
ited research into the management of subacute LBD
[27], and developing effective treatments for this group
represents an opportunity to prevent the transition to
chronic symptoms [126].
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assess treatment integrity fo rb o t ht h es p e c i f i cp h y -
siotherapy treatment group and the advice group
[127,128]. A comprehensive treatment manual, initial
training of physiotherapists, a monthly teleconference
involving all treating physiotherapists, clinical notes
directing physiotherapists along decision making algo-
rithms, reviewing the clinical notes of every participant
at three points during their treatment program, and the
use of standardised participant information sheets are
methods chosen to ensure that all participants receive
treatment from physiotherapists that is standardised,
accountable, and reproducible [127,128]. However, the
algorithmic approach permits some flexibility in the
selection and implementation of treatment components
to ensure that treatment is relevant and specific for as
many participants as possible. One example of this flex-
ibility lies with exercises that can be implemented as
part of the specific motor control training inherent in
the protocols for all subgroups. Once improved motor
control has been achieved in non-weight bearing posi-
tions, physiotherapists will be encouraged to design
exercises relevant to each participant’sf u n c t i o n a lg o a l s .
A participant with an interest in returning to golf for
example could be taught a progression of resisted trunk
rotation exercises whilst activating the transversus abdo-
minis. This could progress to putting with a golf club,
followed by chipping, followed by attending the driving
range and finally progressing to the golf course.
The absence of a placebo control, along with the differ-
ent number of sessions that will be provided to each
group, could be perceived as limitations of the trial. How-
ever, this will be a pragmatic RCT comparing our classifi-
cation-based treatment protocols to advice in its usual
clinical form. Advice is typically administered over 1-2 ses-
sions [35-37], and in this form it is known to be effective
[35-37] and recommended in all international LBD guide-
lines [34]. Other LBD trials that have involved a similar
imbalance in the number of sessions delivered to each
group have found no differences in outcomes [129-131]. It
has also been shown that the placebo effect (in compari-
son to no treatment) typically accounts for only small
standardised mean differences of approximately 0.3 for
participant-reported pain outcomes, equivalent to 3.2-6.5
points on a 100 point pain scale [132-134].
Given the nature of the interventions, it is not possible
to blind physiotherapists and participants in this trial,
although blinded scoring and entry of outcome question-
naires will be employed. We will however educate phy-
siotherapists and participants regarding the validity of
both treatment arms and inform them that both have a
realistic chance of benefiting participants. We will also
inform them that there is no existing evidence to suggest
that one treatment approach is superior to the other.
We know of one completed trial [135] and two trials
currently in progress [136,137] using classification prin-
ciples to direct the treatment approach for participants.
While the principle of sub-grouping is being utilised in
all of these trials, each targets different subgroups, dif-
ferent treatment protocols and different populations to
ours. The results of these trials will be of interest in
determining which classification and treatment protocols
have the greatest potential to benefit people with LBD.
We hope to complete enrolment for the trial by the
end of 2011, with all 12-month follow-up data expected
by the end of 2012.
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